1. Membrane Transporter/Ion Channel
  2. Potassium Channel
  3. Quinidine hydrochloride monohydrate

Quinidine hydrochloride monohydrate 

Cat. No.: HY-B1302 Purity: 99.32%
Handling Instructions

Quinidine hydrochloride monohydrate is a clinical anti-arrythmic drug which is also a potent blocker of K+ channel with an IC50 of 19.9 μM.

For research use only. We do not sell to patients.

Quinidine hydrochloride monohydrate Chemical Structure

Quinidine hydrochloride monohydrate Chemical Structure

CAS No. : 6151-40-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
100 mg USD 60 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Quinidine hydrochloride monohydrate:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Quinidine hydrochloride monohydrate is a clinical anti-arrythmic drug which is also a potent blocker of K+ channel with an IC50 of 19.9 μM.

IC50 & Target

IC50: 19.9 μM (K+ channel)[1]

In Vitro

Quinidine hydrochloride monohydrate blocks WT mSlo3 (KCa5.1) channels with an IC50 of 19.9±1.41 μM and Hill slope of 1.15±0.15 (n=7). Again, the potency of inhibition by Quinidine hydrochloride monohydrate is higher for F304Y mSlo3 (IC50 of 2.42±0.60 μM, n=9, P<0.005; Hill slope of 0.98±0.12), but lower with R196Q mSlo3 (IC50 of 38.4±6.77 μM, n=5, P<0.001; Hill slope of 1.05±0.16). The inhibition of F304Y mSlo3 by Quinidine hydrochloride monohydrate is observed to have some time dependence[1].

In Vivo

Direct application of Quinidine hydrochloride monohydrate on the sciatic nerve produces a dose-related decrease in amplitude at ascending somato-sensory evoked potential (SSEP) and descending compound muscle action potentials (CMAP) when comparing baseline with other time points, or when comparing the experimental left limb to the right contra-lateral glucose-treated limb. The latencies of SSEPs and CMAP potentials after Quinidine hydrochloride monohydrate applications are increased compare to baseline and the contralateral side[2].

Clinical Trial
Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 106.7 mg/mL (281.61 mM; Need ultrasonic and warming)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6393 mL 13.1964 mL 26.3929 mL
5 mM 0.5279 mL 2.6393 mL 5.2786 mL
10 mM 0.2639 mL 1.3196 mL 2.6393 mL
*Please refer to the solubility information to select the appropriate solvent.
References
Cell Assay
[1]

Mouse (m) Slo3 (KCa5.1) channels or mutant forms are expressed in Xenopus oocytes and currents recorded with 2-electrode voltage-clamp. Gain-of-function mSlo3 mutations are used to explore the state-dependence of the inhibition. The interaction between Quinidine hydrochloride monohydrate and mSlo3 channels is modelled by in silico docking[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

24 rats are randomly divided into three groups with eight rats in each group. Groups Q1, Q3, and Q5 receive Quinidine hydrochloride monohydrate 1, 3, and 5 μmol, respectively, in 5 % glucose 0.1 mL. The sciatic nerve is exposed by making an incision from the left sciatic notch to the distal thigh. The subcutaneous tissue is bluntly dissected to expose the biceps femoris. The sciatic nerve is freed from its investing fascia. The procedure is then repeated on the right side. The somato-sensory evoked potential (SSEP) and compound muscle action potentials (CMAP) are recorded at baseline, immediately after Quinidine hydrochloride monohydrate treatment, then every 15 min thereafter for 1 h, then every 30 min thereafter for 3 h. The animals are allowed to recover and then kept separately for 2 weeks. After performing behavioral examinations, electrophysiological examinations are performed with the animals under intra-peritoneal anesthesia[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

378.89

Formula

C₂₀H₂₇ClN₂O₃

CAS No.

6151-40-2

SMILES

C=C[[email protected]]1C[[email protected]](CC[[email protected]]1C2)[[email protected]@]2([H])[[email protected]@H](O)C3=CC=NC4=CC=C(OC)C=C34.[H]Cl.[H]O[H]

Shipping

Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Quinidine hydrochloride monohydrate
Cat. No.:
HY-B1302
Quantity:

Quinidine hydrochloride monohydrate

Cat. No.: HY-B1302